NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
82.25 USD   -0.96%
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results

06/03/2022 | 11:09am EDT

By Josh Beckerman


Novocure Ltd. shares were down 5% to $80.59, and Zai Lab Ltd. American depositary receipts were up 8% at $30.86 after the companies reported results from a study of Tumor Treating Fields.

The EF-31 phase 2 pilot study tested Tumor Treating Fields together with standard-of-care (chemotherapy alone or in combination with trastuzumab for HER2-positive patients) in patients with gastric adenocarcinoma, the companies said.

The study met its primary endpoint of objective response rate with "supportive signals across secondary endpoints." The companies said the "outcomes are encouraging in a historically difficult-to-treat cancer."


Write to Josh Beckerman at josh.beckerman@wsj.com


(END) Dow Jones Newswires

06-03-22 1309ET

Stocks mentioned in the article
ChangeLast1st jan.
NOVOCURE LIMITED -0.96% 82.25 Delayed Quote.9.55%
ZAI LAB LIMITED -4.48% 43.52 Delayed Quote.-30.76%
All news about NOVOCURE LIMITED
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -105x
Yield 2022 -
Capitalization 8 615 M 8 615 M -
EV / Sales 2022 16,0x
EV / Sales 2023 15,0x
Nbr of Employees 1 167
Free-Float 86,7%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 82,25 $
Average target price 94,25 $
Spread / Average Target 14,6%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED9.55%8 699
SHOCKWAVE MEDICAL, INC.58.95%10 416
MASIMO CORPORATION-43.46%8 898
PENUMBRA, INC.-41.46%6 430
GETINGE AB-43.10%5 918
ASAHI INTECC CO., LTD.9.79%5 488